Incorporation of 3’-Azido-3’-deoxythymidine into Cellular DNA and Its Removal in a Human Leukemic Cell Line
Authors:
- Milbrey C. StarnesMSMilbrey C. Starnes
- Yung-Chi ChengYCYung-Chi Cheng
- 1 January 1990
- journal article
- research article
- Published by Cognizant, LLC in Cancer Communications
- Vol. 2 (1) , 55-62
Abstract
3′-Azido-3′-deoxythymidine (AZT) is currently used in the treatment of patients with the acquired immunodeficiency syndrome (AIDS); this often, however, results in hematological toxicity. Although the mechanism of toxicity is not clear, it is thought to result in part from incorporation of AZT into DNA, which causes chain termination. In order to investigate the mechanism of AZT toxicity, the relationship between the presence of AZT in DNA of K562 cells, a chronic myelogenous leukemia cell line, and growth inhibition was examined. No growth inhibition was evident at less than 50 μM AZT, although incorporation of AZT into DNA was detected at 10 and 20 μM. This suggested that the presence of AZT in DNA was not sufficient to inhibit cell growth. Removal of AZT from the medium resulted in the removal of AZT from DNA of the cells, indicative of a cellular repair mechanism. Cellular DNA polymerases α, β, γ, and δ from human leukemic cells were inhibited by AZT triphosphate to different degrees, polymerase α being the least potently inhibited. Furthermore, an enzyme with exonucleolytic activity, capable of removing AZT and dideoxycytidine from the correspondingly terminated DNA (in vitro), was obtained from these cells. In summary, AZT was incorporated into DNA at levels that were not toxic, and it could be removed by an exonuclease, which might play a key role in the susceptibility of cells to AZT.Keywords
This publication has 7 references indexed in Scilit:
- In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virusAntimicrobial Agents and Chemotherapy, 1989
- Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.Journal of Experimental Medicine, 1988
- Effector studies of 3′-azidothymidine nucleotides with human ribonucleotide reductaseBiochemical Pharmacology, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitroAntimicrobial Agents and Chemotherapy, 1987
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- NUCLEOSIDE ANALOGS WITH CLINICAL POTENTIAL IN ANTIVIRUS CHEMOTHERAPY - THE EFFECT OF SEVERAL THYMIDINE AND 2'-DEOXYCYTIDINE ANALOG 5'-TRIPHOSPHATES ON PURIFIED HUMAN (ALPHA,BETA) AND HERPES-SIMPLEX VIRUS (TYPE-1, TYPE-2) DNA-POLYMERASES1981